Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Exon Mutation”

159 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 159 results

Large-scale testing (Phase 3)Looking for participantsNCT07182682
What this trial is testing

Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 360
Testing effectiveness (Phase 2)Study completedNCT03780257
What this trial is testing

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

Who this might be right for
Retinitis PigmentosaUsher Syndrome Type 2Deaf Blind+5 more
ProQR Therapeutics 20
Testing effectiveness (Phase 2)UnknownNCT05529134
What this trial is testing

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Who this might be right for
Dystrophic Epidermolysis Bullosa
Phoenicis Therapeutics 8
Not applicableStudy completedNCT05178030
What this trial is testing

The GALLOP-11 Study

Who this might be right for
Gastro-intestinal Stromal Tumors
University Medical Center Groningen 243
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Early research (Phase 1)WithdrawnNCT04958967
What this trial is testing

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc.
Not applicableApproved For MarketingNCT04337112
What this trial is testing

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

Who this might be right for
Muscular Dystrophy, DuchenneDMD
NS Pharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT03434418
What this trial is testing

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Duke University 17
Not applicableApproved For MarketingNCT04599712
What this trial is testing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782
What this trial is testing

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 278
Testing effectiveness (Phase 2)Study completedNCT01217619
What this trial is testing

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Who this might be right for
Non Small Cell Lung Cancer
Baohui Han 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Not applicableStudy completedNCT01215474
What this trial is testing

Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

Who this might be right for
Mutations in Exons 18 to 21
Provitro GmbH 500
Large-scale testing (Phase 3)Active Not RecruitingNCT05048797
What this trial is testing

Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 454
Very early researchNot Yet RecruitingNCT07458919
What this trial is testing

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Who this might be right for
Lung Cancer
Fuzhou General Hospital 94
Testing effectiveness (Phase 2)Active Not RecruitingNCT06087263
What this trial is testing

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Who this might be right for
Gastrointestinal Stromal Tumors
M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)Study completedNCT00874419
What this trial is testing

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 165
Testing effectiveness (Phase 2)Ended earlyNCT01586195
What this trial is testing

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Who this might be right for
Malignant Melanoma
Genentech, Inc. 31
Next Page